Nasdaq:US$15.72 (+0.06) | HKEX:HK$24.75 (+0.75) | AIM:£2.47 (+0.03)
主要股东

和黄医药共发行871,256,270股普通股。于纳斯达克上市的每股美国存托股份(ADS) 相当于五股普通股。

仅作说明:如果转换所有普通股, 则相当于174,251,254股纳斯达克交易的ADS。

就和黄医药而言,其已发行股本中约39.90%并非由公众持有,而是由和黄医药的董事、高级行政人员及长江和记实业有限公司持有。长江和记实业有限公司为和黄医药主要股东。

和黄医药股本中之主要和重大权益的披露受 (i) 英国金融行为监管局(U.K. Financial Conduct Authority)披露指引及透明度规则(Disclosure Rules and Transparency Rules)第 5 章条文规定(已被纳入本公司的组织章程细则);(ii) 美国 1934 年证券交易法的约束;以及 (iii) 香港证券及期货条例(香港法律第571 章)。

就和黄医药所知,持有和黄医药已发行股本之 3% 或以上的股东及其董事的权益载于下表。

最后更新时间:2023年 12月8日

主要股东

股东 持有股份╱拥有权益之股份数目 所占已发行股本的概约百分比
CK Hutchison Holdings Limited (1) 332,574,650 38.18%
M&G Plc (2) 43,173,457 4.96%
CA Fern Parent (3) 40,847,500 4.69%
 
Notes:
The above table sets out the interests of certain shareholders, insofar as HUTCHMED is aware based on public disclosure as of June 30, 2023. Includes the interests and short positions in the shares or underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company under Section 336 of the SFO, or as otherwise notified to the Company and HKEX under Part XV of the SFO. For details of the capacity of each substantial shareholder’s interests, please refer to the “Interests and Short Positions of Shareholders Discloseable under the Securities and Futures Ordinance” section in the 2023 Interim Report. The above table includes Long Positions only – excludes short positions and lending pools.
(1) Please refer to 2023 Interim Report for details. As of July 15, 2021, notified via disclosure form 2 filed with the Hong Kong Stock Exchange on July 19, 2021.
(2) As of November 2, 2023, notified via disclosure form 2 filed with the Hong Kong Stock Exchange on November 3, 2023.  An aggregated 44,433,217 ordinary shares (long position) are held by M&G Plc indirectly through its certain subsidiaries.
(3) CA Fern Parent is wholly owned by several entities which are, by and through their control affiliates (including their respective general partners), ultimately controlled (directly or indirectly) by The Carlyle Group Inc., but The Carlyle Group Inc. has no beneficial interest in the underlying securities of the Company. As of June 30, 2021, notified via disclosure form TR-1 filed on AIM on July 2, 2021.

董事

董事 持有股份╱
相关股份数目
所占已发行股本的概约百分比
苏慰国 8,162,525 0.94%
郑泽锋 2,695,625 0.31%
杜志强 2,466,185 0.28%
施熙德 1,200,000 0.14%
Dan ELDAR 150,660 0.02%
莫树锦 136,705 0.02%
Paul CARTER 108,925 0.01%
Graeme JACK 86,695 0.01%
杨凌 0 0%
(总计: 15,007,320)  
 
Notes:
As of September 15, 2023.
Includes the interests and short positions of the Directors and chief executive of the Company in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “SFO”)) which were notified to the Company and The Stock Exchange of Hong Kong Limited (the “HKEX”) pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which the Directors and chief executive of the Company were deemed or taken to have under such provisions of the SFO), or which were recorded in the register required to be kept by the Company pursuant to Section 352 of the SFO, or as otherwise notified to the Company and the HKEX pursuant to the Code on Dealings in Shares by Directors adopted by the Company. For details of the capacity and nature of each Director’s interests, please refer to the “Disclosure of Interest” section in the 2023 Interim Report.